Skip to main content

Table 2 Patient characteristics at the 12-month follow-up visit

From: 1-year prospective real life monitoring of asthma control and quality of life in Italy

 

Total

Controlled

Partly controlled

Uncontrolled

Overall p-value

Number of patients, n (%)

739

598 (80.9)

87 (11.8)

54 (7.3)

 

Smoking habits, n (%) (1)

    

0.437

  Current smokers

136 (18.4)

113 (18.9)

14 (16.1)

9 (16.7)

 

  Non-smokers

468 (63.3)

384 (64.2)

50 (57.5)

34 (63.0)

 

  Ex-smokers (2)

128 (17.3)

97 (16.2)

21 (24.1)

10 (18.5)

 

  Not available

7 (0.9)

4 (0.7)

2 (2.3)

1 (1.9)

 

Improvement of 3 points in ACT score, n (%)

642 (86.9)

572 (95.7)

55 (63.2)

15 (27.8)

<0.001(3)

Quality of life, n

733

593

86

54

 

  EQ-5D(4) score, mean (SD)

0.87 (0.19)

0.91 (0.13)

0.71 (0.23)

0.62 (0.30)

<0.001(5)

  EQ-5D(4) VAS score, mean (SD)

80.0 (13.6)

83.8 (10.2)

67.2 (12.1)

58.9 (16.0)

<0.001(6)

Antiasthmatic therapy, n (%) (7)

     

  No therapy

59 (8.0)

55 (9.2)

3 (3.5)

1 (1.9)

-

  ICS /LABA

602 (81.5)

484 (80.9)

72 (82.8)

46 (85.2)

-

  LTRA

237 (32.1)

165 (27.6)

42 (48.3)

30 (55.6)

-

  ICS

71 (9.6)

55 (9.2)

7 (8.1)

9 (16.7)

-

  Short-acting β2agonist

42 (5.7)

21 (3.5)

13 (14.9)

8 (14.8)

-

  1. (1) Smoking habits was reported only at the cross-sectional phase visit; (2) Patients who stopped smoking since at least one year; (3) Bonferroni’s corrected p < 0.001 for all comparisons; (4) EQ-5D: EuroQoL-5D questionnaire; (5) Bonferroni’s corrected p < 0.001 patients with controlled asthma vs. patients with partly controlled and uncontrolled asthma; Bonferroni’s corrected p = 0.060 patients with partly controlled asthma vs. patients with uncontrolled asthma; (6) Bonferroni’s corrected p < 0.001 patients with controlled asthma vs. patients with partly controlled and uncontrolled asthma; Bonferroni’s corrected p = 0.004 patients with partly controlled asthma vs. patients with uncontrolled asthma; (7) Data are percentage of patients in each category of asthma control reporting therapies for at least 5 consecutive days in the last 3 months; patients could have more than one pharmacologic class therapy; ICS: inhaled corticosteroids; LABA: long-acting β2 agonist; LTRA: leukotriene receptor antagonists.